Article Text

Download PDFPDF
Magnesium and headache after aneurysmal subarachnoid haemorrhage
  1. S M Dorhout Mees1,
  2. D Bertens1,
  3. H B van der Worp1,
  4. G J E Rinkel1,
  5. W M van den Bergh2
  1. 1Rudolf Magnus Institute of Neuroscience, Department of Neurology, Utrecht, The Netherlands
  2. 2Department of Intensive Care, University Medical Center Utrecht, Utrecht, The Netherlands
  1. Correspondence to Sanne M Dorhout Mees, Department of Neurology, Room G03.228, University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands; s.m.dorhoutmees{at}


Background In patients with aneurysmal subarachnoid haemorrhage (SAH), headache typically is severe and often requires treatment with opioids. Magnesium has analgesic effects in several conditions, but whether it reduces headache after SAH is unknown.

Methods In a cohort of 108 SAH patients included in the randomised controlled trial Magnesium in Aneurysmal Subarachnoid Haemorrhage-II (MASH-II), severity of headache was regularly assessed on an 11-point scale until day 10 after SAH. Headache was treated according to a standardised protocol with acetaminophen, codeine, tramadol or piritramide. Serum magnesium levels were assessed every other day. Differences in mean headache scores between patients with mean high (>1.0 mmol/l) and normal (≤1.0 mmol/l) magnesium levels were analysed with a Student t test. Crude and adjusted ORs for the use of codeine, tramadol and piritramide for patients with high versus normal magnesium levels were calculated with logistic regression.

Results The 61 patients with high magnesium levels had lower mean headache scores (4.1) than the 47 patients with normal magnesium levels (4.9; mean difference, 0.8; 95% CI 0.1 to 1.6) and required less tramadol (adjusted OR, 0.3; 95% CI 0.1 to 0.7) or piritramide (adjusted OR 0.2; 95% CI 0.1 to 0.5). There were no differences in the use of acetaminophen or codeine.

Conclusion In SAH patients, elevated serum magnesium levels are associated with slightly less severe headache and less frequent use of opioids. These data imply that intravenous magnesium therapy, besides a supposed beneficial effect on outcome, also provides pain relief for SAH patients, for whom it might also improve functional outcome.

  • Subarachnoid haemorrhage
  • magnesium sulphate
  • headache
  • analgesics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This study was partly sponsored by the Netherlands Heart Foundation, grant 2005B16.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the METC Utrecht, The Netherlands.

  • Provenance and peer review Not commissioned; externally peer reviewed.